1

CURRICULUM VITAE

John M. Bertoni, M.D., Ph.D. Creighton University Medical Center

Department of Neurology 601 North 30th Street, Suite 5300

Omaha NE 68131 402-280-4686 Voice 402-449-4370 Fax

I. Personal Data Birth Place: Ann Arbor, Michigan Citizenship Status: U.S.A. II. Education 1967 Honors A.B., Xavier University, Cincinnati, Ohio 1971 M.D., University of Michigan, Ann Arbor, Michigan 1979 Ph.D., University of Michigan, Ann Arbor, Michigan III. Post-Graduate Training 1971-1972 Intern, St. Joseph Mercy Hospital, Ann Arbor, Michigan 1972-1975 Resident in Neurology, University of Michigan, Ann Arbor, Michigan 1975-1979 Ph.D. Neuroscience Program, University of Michigan, Ann Arbor, Michigan 1976-1978 Fellow in Neurochemistry, University of Michigan, Ann Arbor, Michigan IV. Academic Appointments 7/75-6/79 Instructor of Neurology, University of Michigan, Ann Arbor, Michigan 7/79-8/82 Assistant Professor of Medicine (Neurology), University of Texas Health Science Center at San Antonio 8/82-6/88 Associate Professor of Neurology, Jefferson Medical College, Philadelphia, Pennsylvania 7/88-9/88 Professor of Neurology, Jefferson Medical College, Philadelphia, Pennsylvania 9/89-pres Professor and Chairman of Neurology, Creighton University, Omaha, Nebraska 12/89-pres Clinical Professor of Internal Medicine (Neurology), Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska 2/92-pres Professor of Biomedical Sciences, Creighton University, Omaha, Nebraska 11/93-pres Professor of Pharmacology, Creighton University, Omaha, Nebraska

2

V. Other Appointments 7/75-6/76 Assistant Chief and Acting Chief, Neurology Service, Ann Arbor Veterans Administration Hospital, Ann Arbor, Michigan 7/76-6/79 Consultant and Clinic Supervisor, University Hospital, Ann Arbor, Michigan 7/78-6/79 Consultant, Wayne County General Hospital, Heloise, Michigan 7/79-8/82 Consultant and Attending Physician, Bexar County Hospital and Audie Murphy Veterans Administration Hospital, San Antonio, Texas 7/79-8/82 Director, Adult Seizure Clinic, Robert B. Green Hospital, San Antonio, Texas 9/82-9/88 Consultant and Attending in Neurology and Electroencephalographer, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania 6/85-9/88 Consultant and Director, Movement Disorders Clinic, Veterans Administration Hospital, Wilmington, Delaware 6/85-9/88 Director, Movement Disorders Clinic, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania 6/87-9/88 Director, Institutional Review Board, Thomas Jefferson University, Philadelphia, Pennsylvania (dates approximate) 9/88-8/89 Consultant, Providence Hospital, Southfield, Michigan 9/89-pres Co-director, Creighton-Nebraska Neurology Residency Training Program 9/89-pres Chief, Neurology Service; Electroencephalographer, Creighton University Medical Center, Omaha, Nebraska 10/89-pres Consultant, University of Nebraska Medical Center, Omaha, Nebraska 6/90-6/94 Co-investigator, Movement Disorders Clinic, University of Nebraska Medical Center, Omaha, Nebraska 6/94-11/96 Director, Movement Disorders Clinic, University of Nebraska Medical Center, Omaha, Nebraska 6/94-pres Director, Movement Disorders Clinic, Creighton University Medical Center, Omaha, Nebraska 2/97-pres Co-director, Creighton St. Joseph Hospital Stroke Team, Creighton University

Medical Center, Omaha, Nebraska VI. Certification and Licensure Certification Board Certification in Neurology, 1977, #16610 State Licenses Held Michigan, 1972, Permanent, #30976 Pennsylvania, 1982, Permanent, #MD 027355E Nebraska, 1989, Permanent, #18069

3

VII. Professional Affiliations Professional and Scientific Organizations and Societies 1972-pres American Association for the Advancement of Science 1973-pres American Academy of Neurology 1977-pres American Society for Neurochemistry 1979-1982 San Antonio Neurology Association 1979-1980 Michigan Neurological Association 1980-1982 Texas Neurological Association 1980-pres International Society for Neurochemistry 1982-pres Society for Neuroscience 1989-pres Association of University Professors of Neurology 1989-pres Omaha Midwest Clinical Society 1989-pres Nebraska Academy of Neurologists and Neurosurgeons 1989-pres Nebraska Medical Association 1991-pres American Neurological Association Offices Held in Professional Organizations 1983-1986 Council, Philadelphia Society for Neuroscience 1989-2005 Creighton University Medical Center Executive Committee 1989–present Creighton University Medical Center Leadership Council 1990-1991 Section Chairman on Neuropsychiatry, Omaha Midwest Clinical Society 1992-1995 Vice-President, Executive Committee, St. Joseph Hospital - Creighton

University Medical Center Medical Staff. 1995-1997 Secretary, Board of Directors, Creighton Medical Associates 1996-1998 Executive Committee, St. Joseph Hospital and Creighton Medical Associates 1998 Alegent Health/Creighton St. Joseph Regional Healthcare System Strategic

Partnership: Rehab Work Team 1999-2001 Executive Operating Committee, Creighton University School of Medicine 1997-2001 Creighton Medical Associates Board of Directors 2004-present Credentials Committee, Creighton University Medical Center 2003-present AAMC Careers in Medicine, Advisor VIII. Honors and Awards 1959-1960 Tuition Scholarship, University of Detroit High School 1963-1967 Full Tuition Scholarship, Honors A.B. Program, Xavier University 1970 Galens Honorary Medical Society, University of Michigan 1976-1978 National Research Service Award (NIH F32-N505193) 1981 Teacher Investigator Development Award (NIH 1 KO7 NS00555) 1998 Summa Cum Laude Citation, American Society of Radiology 1997 Summa Cum Laude Citation, American Society of Neuroradiology 1997 Cum Laude Citation, American Society of Neuroradiology

4

IX. Editorial Duties Ad hoc reviewer for Journal of Neurochemistry Ad hoc reviewer for Neurology Ad hoc reviewer for Biochemical Pharmacology Ad hoc reviewer for Brain Research Editorial Board, Neuropharmacology X. Contributor/Clinical Consultant Neurologic Disorders, 1985, Springhouse Corp, Book Division, Springhouse, Pennsylvania Signs and Symptoms, 1985, Springhouse Corp, Book Division, Springhouse, Pennsylvania Yearbook 86/87, 1986, Springhouse Corp, Book Division, Springhouse, Pennsylvania Signs and Symptoms, 1995, Springhouse Corp, Book Division, Springhouse, Pennsylvania Physician’s Drug Handbook, 9th Ed, Springhouse Corp, Book Division, Springhouse, Pennsylvania Signs and Symptoms, 2001, Springhouse Corp, Book Division, Springhouse, Pennsylvania Illustrated Manual of Nursing Practice, 2002, Lippincott, Williams and Wilkins, Philadelphia XI. Lectures Controlled-Release Sinemet. American Parkinson Disease Association, September 23, 1991. Diagnosis and Treatment of Parkinson's Disease. Platte-Loup Valley Medical Society, October 29, 1991. The Neurologist's Approach: Assessment and Management of Acute Brain Injury. Critical Care Education Committee of St. Joseph Hospital, December 6, 1991. Multiple Sclerosis - An Overview. National Multiple Sclerosis Society, March 5, 1992. Movement Disorders. Introduction to Clinical Medicine Course, Creighton University Medical School, March 25, 1992. Creutzfeldt-Jakob Disease: The Genetic Infectious Dementia. Bergan Mercy Hospital, April 30, 1992. Myasthenia Gravis. University of Nebraska Medical Center, Department of Ophthalmology, January 15, 1993. Management of Multiple Sclerosis. National Multiple Sclerosis Society, March 25, 1993. Dementia and Aphasia. Introduction to Clinical Medicine Course, Creighton University Medical School, March 29, 1993.

5

Movement Disorders. Introduction to Clinical Medicine Course, Creighton University Medical School, April 1, 1993. Environmental Issues in Parkinson's Disease. Omaha Area Parkinson Support and Education Group, April 18, 1993. Parkinson’s Disease and the Environment. Department of Medicine Grand Round Lecture Series, Creighton University Medical Center, May 10, 1993. The Neurological and Mental Status Exam. Neurodiagnostics Department, St. Joseph Hospital, May 12, 1993. Parkinson’s Disease and the Environment. Creighton-Nebraska Neurology Program Grand Rounds, May 21, 1993. Stroke: The Latest in Diagnosis and Treatment. Family Medicine Update, Creighton University Department of Family Practice, May 30, 1993. The Neurologist's Role in the Diagnosis of Parkinson Disease. American Parkinson Disease Association, June 15, 1994. Management of Movement Disorders. Creighton-Nebraska Psychiatry Program, August 17, 1994. Ataxia: How the Brain Controls Movement. Omaha Ataxia Association, September 17, 1994. Parkinson’s Disease. Omaha Parkinson’s Education and Support Group, September 18, 1994. Familial Creutzfeldt-Jakob Disease: Dementia and the Prion Protein Gene. University of Kansas Department of Neurology Grand Rounds, October 21, 1994. CNS Manifestations in Non-Hodgkin's Lymphoma. Creighton Cancer Center Tumor Conference, January 10, 1995. Multiple Sclerosis. National Multiple Sclerosis Society Midlands Chapter, February 16, 1995. Parkinson's Disease: New Looks at Old Ideas. Norfolk Parkinson's Support Group, April 4, 1995. Parkinson's Disease and Prion Protein Dementia. Creighton University and University of Nebraska Department of Psychiatry, April 5, 1995. Mad Cow Disease and Creutzfeldt-Jakob Disease. Channel 7 Health Beat, April 11, 1996. Parkinson's Disease--Overview of Recent Advances. Grand Island Young Parkinson’s Support Group, July 28, 1996.

6

Update on Parkinson's Research. American Parkinson's Disease Regional Symposium, August 1995. Intervention in Parkinson's Disease: Medical Help and Helping Yourself. National Parkinson’s Foundation, Inc., Lincoln Nebraska, August 10, 1996. Epidemiology of Parkinson Disease. National Parkinson’s Foundation, August 11, 1996. Migraine Headaches. Cox Cable Wellness Connection, September 17, 1996. Localization by Neurologic Exam. Internal Medicine Club, November 6, 1996. Prions and Mad Cow Disease: Where's the Beef? American College of Physicians, Nebraska Chapter Scientific Meeting, November 14, 1996. Diffusion MRI and the Creighton Saint Joseph Acute Stroke Program. Creighton Saint Joseph Medical Staff Meeting, March 4, 1997. Pitfalls in Stroke Diagnosis. University of Nebraska Medical Center, Advances in the Management of Acute Ischemic Stroke and Acute Myocardial Infarction, March 7, 1997. Advancements in the Treatment of Parkinson's Disease. Omaha Parkinson's Education and Support Group, March 16, 1997. Stroke and TPA. Harlan Community Hospital Grand Rounds, Harlan, IA, April 17, 1997. Care of the Stroke Patient. Saint Joseph Hospital Educational Programs for Nurses, February 24, 1998. Treatment of Parkinson’s Disease: Present and Future Strategies or What to do Until a Cure Arrives. 1999 Parkinson’s Disease Symposium, September 11, 1999. Update on Parkinson's Disease. Creighton University Neurology Grand Rounds, September 15, 2000. Diagnosis and Management of Headaches. Seventh Annual Update on Primary Care, October 5, 2000. New Parkinson’s Research. American Parkinson’s Disease Association, Omaha, NE, March 12, 2001. Stroke Prevention. Bristol-Myers Squibb, Omaha, NE, March 22, 2001. Chemical and Biological Agents of Warfare. Creighton University Neurology Grand Rounds, October 5, 2001. Parkinson’s Disease and Health Maintenance. West Omaha Diamond Kiwanis Club, Omaha NE,

7

April 10, 2002. The Brain and How It Works. McMillan Junior High, Omaha NE, April 12, 2002. Parkinson’s Disease. Insurance Institute of Nebraska Meeting, Omaha NE, November 12, 2002. Osteoporosis Case Conference. Participating expert. Osteoporosis Conference Room, May 30, 2003. Acute Stroke. Becic Room, CUMC, August 8, 2003. TIA/Strokes. Surgery Department Classroom, CUMC, August 5, 2004. Parkinson’s Disease in Clinical Practice “2004 and Beyond”. Director of symposium and speaker. Crowne Plaza Hotel, Omaha, NE, November 12, 2004. Parkinson’s Disease Management: 2004 and Beyond. CUMC Department of Medicine Grand Rounds, December 22, 2004. Second Annual: Parkinson’s Progress in 2005. Director of symposium and speaker. Omaha Marriott Hotel, Omaha, NE, October 28, 2005. Understanding Parkinson’s Disease. New Cassel Retirement Center, Omaha, NE, August 22, 2006. Overview of Stroke. 5th Annual Nebraska Stroke Symposium, Nebraska Methodist College, Omaha, NE, October 13, 2006. XII. Bibliography Ph.D. Dissertation Bertoni JM: Development of (Na++K+)-Adenosine Triphosphatase in Rat Brain. University of Michigan, 1979. Articles and Chapters Bertoni JM, Siegel GJ: Development of (Na++K+)-ATPase in rat cerebrum: Correlation with Na+-dependent phosphorylation and K+-paranitrophenylphosphatase. J Neurochem 31:1501-1511, 1978. Bertoni JM, Kooi KA: Fibrous dysplasia of the skull with seizures and focal electroencephalographic findings. Dev Med Child Neurol 20:483-487, 1978. Bertoni JM, Siegel GJ: Development of (Na++K+)-ATPase in rat hindbrain: Increments in parallel with Na+-dependent phosphorylation and K+-pnitrophenylphosphatase. J Neurochem 32:573-580, 1979. Bertoni JM, vonLoh S, Allen RJ: The Aicardi syndrome: A report of four cases and review of the

8

literature. Ann Neurol 5:475-482, 1979. Kruczek M, Albin MS, Wolf S, Bertoni JM: Postoperative seizure activity following enflurane anesthesia. Anesthesiology 53:175-176, 1980. Bertoni JM, Alexander GM, Schwartzman RJ: Metrizamide competitively inhibits hexokinase. Trans Amer Neurol Assoc 105:218-220, 1980. Bertoni JM, Schwartzman RJ, Van Horn G, Partin J: Asterixis and encephalopathy following metrizamide myelography: Investigations into possible mechanisms and review of the literature. Ann Neurol 9:366-370, 1981. Bertoni JM, Alexander GM: Studies on the mechanism of toxicity of metrizamide--competitive inhibition of yeast hexokinase. Biochem Pharmacol 30:1137-1138, 1981. Bertoni JM: Competitive inhibition of rat brain hexokinase by 2-deoxyglucose, glucosamine, and metrizamide. J Neurochem 37:1523-1528, 1981. Bertoni JM, Steinman CG: Competitive inhibition of brain hexokinase by metrizamide. Neurology 32:320-323, 1982. Bertoni JM: Inhibition of rat brain microsomal (Na++K+)-ATPase and K+-p-nitrophenylphosphatase by periodic acid. Biochem Biophys Acta 688:101-106, 1982. Bertoni JM: Metrizamide inhibits human brain hexokinase. Neurology 32:884-887, 1982. Casto DJ, Ludden TM, Bertoni JM, Littlefield LC, Sagraves RA, Mackey RW: Urine and plasma free phenytoin concentration correlation. Clin Pharmacol Therap 32:628-634, 1982. Baker FJ, Gossen G, Bertoni JM: Aseptic meningitis complicating metrizamide myelography. AJNR Am J Neuroradiol 3:662-663, 1982. Bertoni JM, Label LS, Sackellares JC, Hicks SP: Supranuclear gaze palsy in familial Creutzfeldt-Jakob disease. Arch Neurol 40:618-622, 1983. Bertoni JM, Weintraub ST: Competitive inhibition of human brain hexokinase by metrizamide and related compounds. J Neurochem 42:513-518, 1984. Bertoni JM, Abraham FA, Falls HF, Itabashi HH: Small bowel resection with vitamin E deficiency and progressive spinocerebellar syndrome. Neurology 34:1046-1052, 1984. Brainard GC, Vaughan, MK, Reiter RJ, Bertoni JM, Sprenkle PM, Alexander GM: Effect of light wavelength on the seasonal collapse of the male Syrian hamster reproductive system. In The Pineal Gland: Endocrine Aspects, GM Brown and SD Wainwright, eds., Pergamon Press, Oxford, 1985.

9

Cho I, Bertoni JM, Hopkins L: Moxalactam myoclonus, seizures, and encephalopathy. Drug Intell Clin Pharm 20:223-224, 1986. Bertoni JM, Sprenkle PM, Rollag MD, Binkley S, Brainard GC: Diurnal variation of cation pump enzyme activity in pineal and seven other brain regions. J Pineal Res 4:33-43, 1987. Bertoni JM, Sprenkle PM, Brainard GC: Effects of different light wavelengths at equal irradiance on testis weight, protein content, and K-paranitrophenylphosphatase activity in the Syrian hamster. Life Sci 40:1479-1486, 1987. Bertoni JM: Overview of gait and movement disorders in the elderly. Compr Ther 14:46-50, 1988. Kerrigan JJ, Bertoni JM, Jaeger SH: Ganglion cysts and carpal tunnel syndrome. J Hand Surg 13:763-765, 1988. Bertoni JM, Sprenkle PM: Inhibitors of cation pump enzyme equally present in normal and ischemic gerbil brain. Life Sci 42:1955-1962, 1988. Bertoni JM, Sprenkle PM: Inhibition of brain cation pump enzyme by in vitro lead ion: Effects of low level [Pb] and modulation by homogenate. Toxicol Appl Pharmacol 93:101-107, 1988. Bertoni JM, Sprenkle PM: Lead acutely reduces glucose utilization in the rat brain, especially in higher auditory centers. Neurotoxicology 9:235-242, 1988. Epple A, Bertoni JM, Hathaway CB: Physiological doses of epinephrine in the human: Chronotropic but not hyperglycemic or catecholaminotropic. J Exp Zool 250:67-72, 1989. Bush DF, Liss CL, Morton A, Sinemet CR Multicenter Study Group [member of Study Group]: An open multicenter long-term treatment evaluation of Sinemet CR. Neurology 39 (11 Suppl 2):101-104, 1989. Chin HW, Bertoni JM, Fruin AH: Positron emission tomography (PET) applied to stereotactic interstitial brain brachytherapy for malignant glioma patients. In Neuro-Oncology, P Paoletti, K Takakura, MD Walker, et al, eds., pp 185-187, 1991. Chin HW, Fruin AH, Bertoni JM, Frick MP, Shiue CY, McClellan G, Lefkowitz D, Taylon C, Bowman BM: Application of positron emission tomography to neurological oncology. Nebr Med J 76:70-73, 1991. Bertoni JM, Sprenkle PM: Low level lead inhibits the human brain cation pump. Life Sci 48:2149-2156, 1991. Bertoni JM, Sprenkle PM, Hanifin JP, Stetson MH, Brainard GC: Effects of short photoperiod on ATPase activities in the testis of the immature Siberian hamster. Biol Reprod 47:509-513, 1992.

10

Bertoni JM, Brown P, Goldfarb LG, Rubenstein R, Gajdusek DC: Familial Creutzfeldt-Jakob disease (codon 200 mutation) with supranuclear palsy. JAMA 268:2413-2415, 1992. Bertoni JM, Sprenkle PM: Effects of in vitro ethanol on the brain cation pump in alcoholics and controls. Biochem Pharmacol 48:435-441, 1994. Strickland D, Bertoni JM, Pfeiffer RF: Descriptive epidemiology of Parkinson's disease through proxy measures. Can J Neurol Sci. 23:279-284, 1996. Block G, Liss C, Reines S, Irr J, Nibbelink D, The CR First Study Group [member of Study Group]: Comparison of immediate-release and controlled-release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. Eur Neurol 37:23-27, 1997. Lieberman A, Ranhosky A, Korts D, Pramipexole Study Group [member of Study Group]: Clinical evaluation of pramipexole in advanced Parkinson's disease: Results of a double blind, placebo-controlled, parallel-group study. Neurology 49:162-168, 1997. Adler CH, Sethi KD, Hauser RA, Davis TL, Hammerstad JP, Bertoni J, Taylor RL, Sanchez-Ramos J, O’Brien CF: Ropinirole for the treatment of early Parkinson's disease. Neurology 49:393-399, 1997. Sethi KD, O’Brien CF, Hammerstad JP, Adler CH, Davis TL, Taylor RL, Sanchez-Ramos J, Bertoni JM, Hauser RA: Ropinirole for the treatment of early Parkinson’s disease. A 12-month experience. Arch Neurol 55:1211-1216, 1998. Lefkowitz D, LaBenz M, Nudo SR, Steg RE, Bertoni JM: Hyperacute ischemic stroke missed by diffusion-weighted imaging. AJNR Am J Neuroradiol 20:1871-1875, 1999. Sprenkle PM, McGee J, Bertoni JM, Walsh EJ: Consequences of hypothyroidism on auditory system function in Tshr mutant (hyt) mice. JARO 2:312-329, 2001. Sprenkle PM, McGee J, Bertoni JM, Walsh EJ: Development of auditory brainstem responses (ABRs) in Tshr mutant mice derived from euthyroid and hypothyroid dams. JARO 2:330-347, 2001. Sprenkle PM, McGee J, Bertoni JM, Walsh EJ: Restoration of auditory function in hypothyroid Tshr mutant mice by thyroxin treatment during development. JARO 2:348-361, 2001. Bertoni JM, Prendes J-L, Sprenkle PM: Long-term medical treatment for Parkinson’s disease. Curr Treat Options Neurol 3:495-506, 2001. Pankratz N, Nichols WC, Uniacke SK, Halter C, Rudolph A, Shults, Conneally PM, Foroud T, Parkinson Study Group [member of Study Group]: Genome screen to identify susceptibility genes for Parkinson’s disease in a sample without parkin mutations. Am J Hum Genet 71:124-135, 2002. Nichols WC, Pankratz N, Uniacke SK, Pauciulo MW, Halter C, Rudolph A, Conneally PM, Foroud

11

T, Parkinson Study Group [member of Study Group]: Linkage stratification and mutation analysis at the parkin locus identifies mutation positive Parkinson’s disease families. J Med Genet 39:489-492, 2002. Faulkner MA, Bertoni JM, Lenz TL: Gabapentin for the treatment of tremor. Ann Pharmacother 37:282-286, 2003. Reider CR, Halter CA, Castellucio PF, Oakes D, Foroud T, Parkinson Study Group [member of Study Group]: Reliability of reported age at onset for Parkinson’s disease. Movement Disorder 18 (3):275-9, 2003. Parkinson Study Group [member of Study Group]: A controlled trial of rotigotine monotherapy in early Parkinson’s disease (the Patch Study). Submitted to Neurology, 2002. Parkinson Study Group [member of Study Group]: A controlled trial of rasagiline in early Parkinson’s disease (the TEMPO Study). Submitted to Ann Neurol, 2002. Pankratz P, Nichols WC, Uniacke SK, Halter C, Rudolph A, Shults C, Conneally PM, Foroud T, Parkinson Study Group [investigator]: Significant Linkage of Parkinson Disease to Chromosome 2q36-37. American Journal of Human Genetics 72:1053-1057, 2003. Foroud T, Uniacke SK, Liu L, Pankratz N, Rudolph A, Halter C, Shults C, Marder K, Conneally PM, Nichols WC, Parkinson Study Group [member of Study Group]: Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson Disease. Neurology 60:796-801, 2003. Pankratz P, Nichols WC, Uniacke SK, Halter C, Murrell J, Rudolph A, Shults CW, Conneally PM, Foroud T, Parkinson Study Group [member of Study Group]: Genome-Wide Linkage Analysis and Evidence of Gene-by-Gene Interactions in a Sample of 362 Multiplex Parkinson Disease Families. Molecular Genetics, in press. Blindauer K, Shoulson I, Parkinsons Study Group [member of Study Group]: A Controlled Trial of Rotigotine Monotherapy in Early Parkinson’s Disease. Arch Neurol. 60:1721-1728, 2003. Shoulson, Fahn, Kieburtz, Stern, Oakes, Siderowf, Blindauer, Oren, Goren, Levy, Plumb, Eyal, Parkinsons Study Group [member of Study Group]: A Controlled, Randomized, Delayed-Start Study of Rasagiline in Early Parkinson Disease. Arch Neurol. 61:561-566, 2004. Nichols WC, Uniacke SK, Pankratz N, Reed T, Simon D, Halter C, Rudolph A, Shults C, Conneally PM, Foroud, T, Parkinsons Study Group [member of Study Group]: Evaluation of the Role of Nurr1 in a Large Sample of Familial Parkinson Disease. Movement Disorders 19: 649-655, 2004. Pankratz N, Uniacke SK, Halter C, Rudolph A, Shults CW, Conneally PM, Foroud T, Nichols WC, Parkinsons Study Group [member of Study Group]: Neurology 62:1616, 2004.

12

Bertoni JM, Elmer L: The Role of MAO-B Inhibitors in the Treatment of Parkinson’s Disease. Parkinson’s Disease, 2005. Schwid, Shoulson, Stern, Oakes, Kieburtz, Fahn, Blindauer, deMarcaida, Fazzini, Chin, Hausen, Gauger, Ondo, Lewitt, Racette, Frei, Parkinson’s Study Group [member of Study Group]: A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated Patients With Parkinson Disease and Motor Fluctuations. Arch Neurol. 62:241-248, 2005. Bertoni J, Kricorian G, Leehey M, Lew MF, Pahwa R, Selegiline Study Group, Valeant International Zydis: Movement Disorders, submitted. Goetz CG, Schwid SR, Eberly SW, Oakes D, Shoulson I, Parkinson’s Study Group [member of Study Group], Tempo and Presto Investigators: Safety of Rasagiline in Elderly Patients with Parkinson’s Disease. Neurology 66:1427-1429, 2006. Nichols WC, Marek DK, Pauciulo MW, Pankratz N, Halter C, Rudolph A, Shults C, Wojcieszek J, Foroud T and the Parkinson Study Group-PROGENI investigators: R1514Q Substitution in LRRK2 is not a Pathogenic Parkinson Disease Mutation. Movement Disorders 22:254-257, 2007. Pankratz N, Pauciulo MW, Elsaesser VE, Marek DK, Halter CA, Rudolph A, Shults CW, Foroud T, Nichols WC and the Parkinson Study Group-PROGENI Investigators: Mutations in LRRK2 Other than G2019S are Rare in a North American-based Sample of Familial Parkinson Disease. Movement Disorders 21: 2257-2260, 2006. Pankratz N, Pauciulo MW, Elsaesser VE, Marek DK, Halter CA, Wojcieszek J, Rudolph A, Shults CW, Foroud T, Nichols WC and the Parkinson Study Group-PROGENI Investigators: Mutations in DJ-1 are Rare in Familial Parkinson Disease. Neuroscience Letters 408(3): 209-213, 2006. Lew M, Pahwa R, Leehey M, Bertoni J, Kricorian G and the Zydis Selegiline Study Group: Safety and Efficacy of Newly Formulated Selegiline Orally Disintegrating Tablets as an Adjunct to Levodopa in the Management of “Off” Episodes in Patients with Parkinson’s Disease. Current Medical Research and Opinion: Vol. 23, No. 4, 741-750, 2007. Abstracts Bertoni JM, Siegel GJ: Two forms of rat cerebral (Na++K+)-adenosinetriphosphatase with differing susceptibility to periodate inhibition. Society for Neuroscience, Anaheim, CA, 1977. Bertoni JM, Falls HF, Alpern M, Kokmen E, Abraham F, Bossemeyer RW: Fat soluble vitamin deficiency syndrome resembling Bassen-Kornzweig disease. American Academy of Neurology Scientific Program, 1978. Bertoni JM, Siegel GJ: Concurrent development of (Na++K+)-ATPase and its putative partial reactions in rat forebrain: Correlation with measured brain Na and K and proposed temporal relationship to proliferation of fine cellular processes. International Society for Neurochemistry,

13

Jerusalem, Israel, 1979. Bertoni JM, Alexander GM, Schwartzman RJ: Metrizamide competitively inhibits hexokinase. Ann Neurol 8:107, 1980. Casto DT, Ludden TM, Littlefield LC, Bertoni JM, Mackey RW: Correlation of urine phenytoin and plasma free phenytoin concentrations. American College of Clinical Pharmacology, 1981. Bertoni JM: Lead ion inhibition of rat brain K-p-nitrophenylphosphatase is age related. International Society for Neurochemistry, Nottingham, UK, 1981. Bertoni JM, Steinman CG: Metrizamide competitively inhibits rat brain hexokinase. International Society for Neurochemistry, Nottingham, UK, 1981. Mercer LF, Bertoni JM: Do factors in ischemic brain suppress (Na++K+)-ATPase activity? Seventh International Joint Conference on Stroke and Cerebral Circulation, February, 1982. Reyes PF, Malherbe HH, Bertoni JM, Parker JC: Histopathologic and in vitro culture studies in a case of primary amoebic meningoencephalitis. American Association of Neuropathology, 1982. Bertoni JM, Label LS, Sackellares JC, Hicks SP: Supranuclear gaze palsy in familial Creutzfeldt-Jakob disease. Neurology 32:A77, 1982. Alexander GM, Schwartzman RJ, Bell RD, Bertoni JM: Simultaneous autoradiographic quantification of cerebral blood flow and metabolism. Neurology 32:A196, 1982. Bertoni JM: Inhibition of human brain hexokinase by analogues of metrizamide. Neurology 33 (Suppl 2):178, 1983. Bertoni JM, Cho I: Severe myoclonus with moxalactam toxicity. Neurology 33 (Suppl 2):200, 1983. Bertoni JM, Sprenkle PM: Low level lead inhibition of brain cation pump enzyme. Ann Neurol 14:139, 1983. Bertoni JM, Felmly WT: Regional effects of in vivo and in vitro lead on the brain cation pump. National Student Research Forum, 1984. Bertoni JM, Felmly WT, Sprenkle PM: Regional brain cation pump susceptibility to lead. American Academy of Neurology, 1984. Bertoni JM, Sprenkle PM: Minimal inhibition of brain cation pump enzyme by acetyl-L-carnitine. Society for Neuroscience, 1984. Bertoni JM, Sprenkle PM: Photoperiod effects on hamster organ wet weight and cation pump

14

activity. American Society for Neurochemistry, 1985. Bertoni JM, Sprenkle PM: L-acetylcarnitine competitively inhibits the brain cation pump enzyme. American Academy of Neurology, 1985. Bertoni JM, Sprenkle PM: Endogenous inhibitors of the cation pump in ischemic brain. Sixth Annual Research Reception, Pennsylvania Affiliate of the American Heart Association, Altoona, PA, September 28, 1985. Bertoni JM, Sprenkle PM: Neonatal lead exposure reduces glucose utilization in adult rat brain. Abstract #157, 17th Annual Meeting, American Society for Neurochemistry, Montreal, Quebec, March 16-21, 1986. Bertoni JM, Sprenkle PM: Search for endogenous cation pump inhibitors in ischemic brain. 59th Scientific Sessions of the American Heart Association, Dallas, TX, November 17-20, 1986. Bertoni JM, Sprenkle PM: Brain cation pump inhibited by "normal" lead levels. American Neurological Association Meeting, San Francisco, CA, October 18-21, 1987. Yee E, Sprenkle PM, Bertoni JM: Manganese has minimal effects on regional rat brain glucose metabolism. Neurology 38 (Suppl 1):418, 1988. Bertoni JM, Sprenkle PM: Human brain cation pump inhibited by low level inorganic lead. American Neurological Association Meeting, Philadelphia, PA, October 3, 1988. Sprenkle PM, Bertoni JM, Hanifin JP, Stetson MH, Brainard GC: Testicular Na,K-ATPase activity in the Djungerian hamster is photoperiod dependent and modulated by UV light. American Society for Photobiology, Boston, MA, July 3, 1989. Bertoni JM, Sprenkle PM: Chronic lead exposure reduces glucose utilization in the developing rat brain. American Academy of Neurology, Miami, FL, May 4, 1990. Sison AS, Dewan N, Schima EM, Hertzler JJ, Bertoni JM: Hydrogen sulfide induced coma with seizures. American Academy of Neurology, Miami, FL, May 4, 1990. Chin HW, Shiue CY, Bertoni J: Positron Emission Tomography study for follow-up assessment of glioma patients treated with surgery and/or radiation therapy. Southern Medical Association, Nashville, TN, October 16, 1990. Chin HW, Fruin AH, Frick MP, Bertoni JM: Use of Positron Emission Tomography in stereotactic brain brachytherapy. 9th Congress of the European Society for Stereotactic and Functional Neurosurgery, Marbella, Spain, September, 1990. Chin HW, Fruin AH, Bertoni JM: Stereotactic Ir-192 radio-implantation therapy for deep-seated

15

high grade brain tumors. 9th Congress of the European Society for Stereotactic and Functional Neurosurgery, Marbella, Spain, September, 1990. Sison AS, Bertoni JM, Aita JF, Angle CR, Dewan N: Hydrogen sulfide (H2S): Delayed death in 2 men with 1 symptomatic survivor. American Academy of Clinical Toxicology, Tucson, AZ, September 13-18, 1990. Chin HW, Fruin AH, Lefkowitz D, Jaeger S, Bertoni J: Positron Emission Tomography (PET) study applied to stereotactic interstitial brain brachytherapy for malignant glioma patients. International Symposium on Advances in Neuro-oncology, San Remo, Italy, September 26-29, 1990. Chin HW, Fruin AH, Jaeger S, Bertoni JM, Taylon C: Positron emission tomography for the therapy planning and response assessment of brain brachytherapy. RSNA-90, Chicago, IL, November 25-30, 1990. Chin HW, Fruin AH, Frick MP, Bertoni JM: Positron Emission Tomography (PET) study for brain brachytherapy of malignant brain tumors. Southern Med J 83 (Suppl 1):85, 1990. Chin HW, Lefkowitz D, Datta R, Bertoni JM: Positron emission tomography (PET) in pre-therapy evaluation and response assessment of brain brachytherapy for brain tumor patients. Southern Med J, 84 (Suppl 2):106, 1991. Chin HW, Bertoni JM: Comprehensive analysis of stereotactic interstitial neuro-brachytherapy for malignant brain tumors. Proceedings of the Second International Neuro-Oncology Conference, 1991. Chin HW, Lefkowitz D, Bertoni J: Positron Emission Tomography (PET) for assessment of brain tumors. The 10th Asia Pacific Cancer Conference, Bejing, China, August 20-23, 1991. Chin HW, Bertoni JM: Comprehensive analysis of stereotactic interstitial neuro-brachytherapy for malignant brain tumors. The Second International Neuro-Oncology Conference, London, UK, March 25-26, 1991. Bertoni JM, Sprenkle PM: Human brain cation pump inhibition by ethanol not different in alcoholism. Ann Neurol 30:312, 1991. Sprenkle PM, Bertoni JM, Ghosh S: Genetic hypothyroidism alters hypothalamic Na,K-ATPase. American Academy of Neurology, 4th Annual Meeting, San Diego CA, May 3-9, 1992. Bertoni JM, Brown P, Goldfarb LG, Gajdusek DC: Familial Creutzfeldt-Jakob disease with the PRNP codon 200lys mutation and supranuclear palsy but without myoclonus or periodic EEG complexes. American Academy of Neurology, 4th Annual Meeting, San Diego, CA, May 3-9, 1992. Bertoni JM, Sprenkle PM, Ghosh S: Adult brain Na,K-ATPase is regionally altered in the genetically hypothyroid mouse. American Society for Neurochemistry, 23rd Annual Meeting,

16

Houston, TX, March 15-20, 1992. Bertoni JM, Sprenkle PM: Genetic hypothyroidism alters hypothalamic Na,K-ATPase activity. American Academy of Neurology, 44th Annual Meeting, San Diego CA, May 3-9, 1992. Bertoni JM, Sprenkle PM: Ouabain inhibition of adult hypothyroid mouse brain Na, K-ATPase. Society for Neuroscience 22nd Annual Meeting, Anaheim, CA, October 25-30, 1992. Bertoni JM, Walsh EJ, McGee J, Sprenkle PM: Auditory deficits in genetically hypothyroid mice. Associate for Research in Otolaryngology, 1993 Midwinter Meeting, St. Petersburg Beach, FL, February 7-11, 1993. Bertoni JM, Aita JF, Gupta N: Parkinsonism-dementia after hydrogen sulfide intoxication. American Neurological Association, Boston, MA, October 19, 1993. Bertoni JM, Sprenkle PM, Adrian TE: Neuropeptide abnormalities in the genetically hypothyroid (hyt/hyt) mouse. First International Congress on Hormones, Brain and Neuropsychopharmacology. Rhodes, Greece, September 13-17, 1993. Strickland D, Bertoni J, Pfeiffer R: Parkinson’s disease and agricultural risk factors in Nebraska. American Academy of Neurology, Washington, DC, May 3, 1994. Liberman A, Pramiprexole Advanced Parkinson Disease Study Group [member of Study Group]: Efficacy and safety of pramipexole in advanced Parkinson's disease patients with "wearing off" phenomena. American Academy of Neurology, March, 1996. Lefkowitz DM, Bertoni JM, Weiner J, Rysavy JA: Echo planar diffusion weighted MRI in routine clinical practice. Symposium on Occlusive Cerebrovascular Disease and Brain Ischemia, New Haven, CT, May 17-19, 1996. Bertoni JM, Sprenkle PM: Genetically hypothyroid mice as movement disorders model. Fourth International Congress of Movement Disorders, June, 1996. Lefkowitz DM, Bertoni JM, Moore J: Stroke mechanisms, MRI correlations, and therapeutic implications. American Society of Neuroradiology, December, 1996. Lefkowitz DM, McIntee MJ, Bertoni JM, Rysavy JA, Grigsby WS, Moore J: MRI diagnosis of hemorrhage: Is CT still necessary? American Society of Neuroradiology, December, 1996. Lefkowitz DM, Bertoni JM, Hoefer SB, Schlaepfer CC, Rysavy JA, Moore J: Secondary ischemic lesions in association with primary stroke events. American Society of Neuroradiology, December, 1996. Lefkowitz DM, Bertoni JM, Rysavy JA, Schlaepfer CC, Hoefer SB, Moor J: Diffusion weighted imaging: Not all that glitters is a stroke. American Society of Neuroradiology, December, 1996.

17

Parkinson Study Group [member of Study Group]: A controlled trial of rasagiline in early Parkinson's disease: Efficacy, safety and tolerability. Ann Neurol 48:489, 2000. Blindauer K, Parkinson Study Group [member of Study Group]: Tyramine challenge to assess the safety of rasagiline monotherapy in a placebo-controlled multicenter trial for early Parkinson's disease (the TEMPO study). Neurology 56:A345, 2001. Pankratz N, Koller DL, Foroud T, Parkinson’s Study Group [member of Study Group]: Power to reconstruct the genotype of a missing individual. Am J Med Genet 67 (Suppl 2):332, 2001. Reider CR, Halter CA, Foroud T, Oakes D, Parkinson Study Group [member of Study Group]: Reliability of self-reporting age of onset for Parkinson’s disease. Mov Disord 16:991, 2001. Threlkeld AJ, Geiger A, Slusarski J, Cooper L, Sprenkle PM, Bertoni JM: Kinematics of free gait and treadmill body weight suspension in subjects with Parkinson's disease. Physical Therapy 2001: The Annual Conference and Exposition of the American Physical Therapy Association, Anaheim CA, June 20-24, 2001. Threlkeld AJ, Cooper LD, Sprenkle PM, Bertoni JM: Kinematic comparison of treadmill gait with body weight suspension between unimpaired subjects and subjects with Parkinson’s disease. World Congress of Biomechanics, Calgary, Alberta, Canada, August, 2002. Bianchine J, Poole K, Woltering F, for the Rotigotine SP 506 Trial Team [member of Study Group]: Efficacy and dose response of the novel transdermally applied dopamine agonist rotigotine CDS in early Parkinson’s disease. Neurology 58 (Suppl 3):A162, 2002. Pankratz ND, Nichols WC, Uniake SK, Rudolph A, Halter C, Shults C, Conneally PM, Foroud T, Parkinson Study Group [member of Study Group]: Genome screen to identify loci contributing to the susceptibility for Parkinson’s disease. American Academy of Neurology, Denver CO, April 17, 2002. Reider C, Halter C, Castelluccio P, Foroud T, Parkinson Study Group [member of Study Group]: Differences in duration from parkinsonian symptom onset to diagnosis among concordantly affected siblings. American Academy of Neurology, Denver CO, April 17, 2002. Nichols WC, Pankratz ND, Uniake SK, Pauciulo MW, Halter C, Rudolph A, Conneally PM, Foroud T, Parkinson Study Group [member of Study Group]: Stratification by linkage rather than age of onset identifies more parkin mutation positive, Parkinson’s disease families. American Academy of Neurology, Denver CO, April 18, 2002. Foroud T, Uniacke SK, Liu L, Pankratz N, Rudolph A, Halter C, Shults C, Conneally PM, Nichols WC, Parkinson Study Group [member of Study Group]: Identification and characterization of parkin mutations among later onset familial PD subjects. Submitted to American Neurological Association, 2002.

18

Bertoni JM, Sprenkle P, Strickland D, Noedel N: Initial case retrievals from the Nebraska State Parkinson’s Disease Registry. Sixteenth Annual Symposium on Etiology, Pathogenesis and Treatment of Parkinson’s Disease and Other Movement Disorders, New York NY, October 13, 2002. Bertoni JM, Sprenkle P, Strickland D, Noedel N: Evaluation of Parkinson's disease in entrants on the Nebraska State Parkinson's Disease Registry. American Academy of Neurology, 55th Annual Meeting, Honolulu HI, March 29-April 5, 2003 (submitted). M Lew, R Pahwa, M Leehey, J Bertoni: Long-Term Efficacy and Safety of Zydis® Selegiline in Parkinson’s Disease (submitted) ICPDMD Waters CH, Sethi KD, Hauser RA, Molho E, Bertoni JM: Zydis Selegiline Reduces Off Time in Parkinson’s Disease Patients with Motor Fluctuations: A 3-Month, Randomized, Placebo-Controlled Study. Movement Disorders. 4:426-432, April 2004. Schwid SR, and Parkinson Study Group. Safety of Rasagiline in Combination with Serotonin Reuptake Inhibitors. American Neurological Association 130th Annual Meeting, San Diego, CA, September 27, 2005. Bertoni JM, Arlette JP, Fernandez HH, Frei K, Gordon MF, Hassan MN, Isaacson SH, Lew MF, Molho E, Ondo WG, Phillips TJ, Singer C, Sutton JP, Wolf JE Jr.: Parkinson’s Disease and Melanoma: An Epidemiologic Evaluation. The Movement Disorder Society’s 10th International Congress of Parkinson’s Disease and Movement Disorders, Kyoto, Japan, October 28-November 2, 2006. Contributor Schweiss K: Combating strokes: What you need to know about prevention and rehabilitation. Omaha Magazine, July-August, 2000, pp 73-75. Meyers S: Six facts to know about Parkinson's disease. Family Safety and Health, Spring, 2001, pp 30-31. Update on Stroke. KMTV, Omaha NE, May 7, 2002. Parkinson’s Disease. Aired on “Creighton in the Community”, Omaha, NE, June 24, 2005. XIII. Grants Inorganic Lead Poisoning and the Cation Pump, National Institutes of Health, 7/81-6/83. Cation Pump in Mammalian Brain: Basic and Applied Investigation, National Institutes of Health Teacher-Investigator Development Award, 7/83-6/84.

19

Endogenous Inhibitors of the Cation Pump in Ischemic Brain, American Heart Association Pennsylvania Chapter, 7/85-6/86. Neurotoxicity of Low Level Inorganic Lead: Effects on Cerebral Glucose Metabolism and Cation Pumping, Jefferson Medical College, 2/88-1/89. Environmental Studies of Parkinson's Disease in Nebraska, American Parkinson’s Disease Association, (UNMC) 10/91-10/92. Hypothyroidism and Neuropeptide Development, Creighton University Health Futures Foundation, 11/91-10/92. Correlative Anatomic, Biochemical, and Physiologic Analysis of Hypothyroid-Induced Deafness, Deafness Research Foundation, 1/92-12/93. Double-Blind, Placebo-Controlled, Parallel-Group Comparison to Assess the Safety, Tolerance, and Efficacy of Pramipexole in Advanced Parkinson’s Disease, Boehringer Ingelheim Pharmaceuticals, Inc., (UNMC) 7/93-6/96. Long Term Use of Cabergoline in Patients Who Have Completed the Phase III Efficacy Study, Adria Laboratories, (UNMC) 5/93-4/94, 1/96-12/97. Ropinirole Six-Month Extension Study, SmithKline Beecham, (UNMC) 3/93-9/94. Long Term Use of Open Label Pramipexole (0979) in Patients Who Have Completed the (0679) Efficacy Study, Boehringer Ingelheim Pharmaceuticals, 8/95-12/97. Noncomparative, Open-Label Study to Identify TASMAR Dosage Regimen in Nonfluctuating Parkinson's Disease Patients Treated with Sinemet, With Follow-Up Extension of TASMAR, Roche Laboratories, 1/96-12/97. The Effect of Citicoline (500) mg on the Evolution of Lesion Volume in Human Stroke Using Diffusion Weighted MRI, Interneuron Pharmaceuticals, 12/96-12/97. A Prospective Multi-Center Dose-Ranging Study of Intra-Arterial Thrombolysis in Acute Middle Cerebral Artery Distribution Thromboembolic Stroke, Part II, Abbott Laboratories, 2/97-12/97.

Assessment of the Efficacy and Safety of Eliprodil in Patients with Acute Ischemic Stroke (LES02), 5/96-7/96.

A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Phase III Clinical Trial for the Efficacy, Tolerability, and Safety of Two Doses of Rasagiline Mesylate in Early, Untreated Parkinson’s Disease Patients Not Treated with Levodopa, Teva Pharmaceuticals, 1/98-3/00.

Double-Blind, Placebo-Controlled, Safety, Efficacy, and Dose-Response Trial of Two Intravenous

20

Doses of BMS-204352 in Patients with Acute Stroke, 7/98-8/00.

A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy of Zydis Selegiline 1.25mg to 2.5mg qd with Placebo as an Adjunct in the Management of Parkinsonian Patients Being Treated with Levodopa Who Exhibit Deterioration in the Quality of Their Response to This Therapy, Elan Pharmaceuticals, 8/98-12/99.

A Multicenter, Open-Label, Phase III Study for the Safety, Tolerability and Clinical Effect of Rasagiline Mesylate in Patients with Parkinson’s Disease, Protocol TVP-1012/233, Teva Pharmaceuticals, 1/99-present.

Parkinson’s Disease Collaborative Study of Genetic Linkage, ‘PROGENI’, NIH/Indiana University, 3/99-present.

A Phase III Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Study of the Effect of Riluzole 50mg bid or 100mg bid for Two Years on the Progression of Parkinson’s Disease in 1050 Patients, Aventis Pharmaceuticals, 8/99-11/01.

A Phase III Multicenter, Double Blind, Parallel Group, Placebo-Controlled Study of the Effect of Riluzole 50mg bid or 100mg bid on the Progression of Parkinson’s Disease in Patients Treated with L-Dopa or Dopamine Agonist, Aventis Pharmaceuticals, 8/99-11/01.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Escalating Transdermal Doses of SPM 962 in Subjects with Early Stage Parkinson’s Disease-‘PATCH’, Schwarz Pharma, Inc., 12/99-2/01.

An Open Extension Study of the Safety and Efficacy of Zydis Selegiline 1.25 to 2.5mg qd as an Adjunct in the management of Parkinsonian Patients Being Treated with Levodopa (Protocol #Z/SEL/97/027) Incorporating Amendments 1, 2, 3, 4, 5, and 6), Elan Pharmaceuticals, 1/00-3/03.

Epidemiology of Parkinson's Disease and Farm Risk Factors, NIH, Co-PI, 1/00-9/02.

A Multicenter, Randomized, Double-Blind, Double Dummy, Parallel Group Study Comparing TV-1203/Carbidopa Dispersible Tablets with Levodopa/Carbidopa Tablets in Advanced Parkinson’s Disease Patients with Motor Fluctuations, Teva Pharmaceuticals, 5/00-5/03. (TV-1203/111) $50,456 A Multicenter, Double Blind, Placebo-Controlled Study of the Tolerability and Effect of Entacapone in Parkinson's Subjects with End-of-Dose Wearing Off Symptoms Occurring No Earlier than 4 Hours after Their Most Recent Levodopa/Carbidopa Dose (Comtan US01 Study), Novartis Pharmaceuticals, 9/00-9/01. A Multicenter, US and Canada, Double Blind, Randomized, Placebo-Controlled, Parallel Group Study for the Efficacy, Tolerability and Safety of Rasagiline Mesylate in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations (Protocol TVP-1012-133 - PRESTO), Teva Pharmaceuticals, 9/00-9/03, $78,197

21

A Phase III, Multinational, Multicenter, Double Blind, Parallel Group, Placebo-Controlled, Randomized Extension of Study 320 of the Effect of Riluzole on the Progression of Parkinson’s Disease, Aventis Pharmaceuticals, 7/01-11/01. Relationship of Environmental Heavy Metal Burden to Parkinson’s Disease in Nebraska, Creighton University, 10/01-12/02. An Open Extension Study of the Safety and Efficacy of Zydis Selegiline 1.25 to 2.5 qd as an adjunct in the Management of Parkinsonian Patients being treated with Levodopa. (Protocol No: Z/SEL/97/027 incorporating amendments 1,2,3,4,5 & 6. 1/01 to 1/03, $16,680 Parkinson's Disease Collaborative Study of Genetic Linkage, 'PROGENI' 3/99 to present $30,260 A Multicenter, Open-Label Phase III Study for the Safety, Tolerability and Clinical Effect of Rasagiline Mesylate in Patients with Parkinson' Disease, Protocol TVP-1012/233 1/99 to present, $40,953 A Bi-national Multicenter, Open-Label Study to Evaluate the Safety and tolerability of TV-1203-/Carbidopa Dispersible Tablets in Advanced Parkinson's Disease Patients with Motor Fluctuation Treated with chronic Levodopa/Carbidopa Therapy 1/01-5/03, $15,512 A Phase III, Double blind, Placebo-Controlled, Randomized Study Comparing the Efficacy, Safety and tolerability of Sumanirole versus Placebo or Ropinirole in Patients with Early Parkinson's Disease, 10/01 to 4/03, $94,188 Pharmacogenomics Blood Sampling Protocol for Sumanirole (Protocol: 666E-CNS-0614-001) 4/02-4/03, $500 An Active Extension of the TVP-1012/133 (PRESTO) Study: A Binational, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Tolerability of Rasagiline Mesylate in Advanced Parkinson's Disease (PD) Patients with Motor Fluctuations Treated With Chronic Levodopa/Carbidopa Therapy (Protocol TVP-1-12/135) 10/2001 to present, $29, 400 Sumanirole: Open-label, Long Term, Flexible Dose Study of Safety, Tolerability, and Therapeutic Response in Patients with Parkinson’s disease. (Protocol: M/2760/0011) 1/02-present, $120,300 A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Efficacy and Safety of CEP-1347 in Patients With Early Parkinson’s Disease - (PRECEPT) 4/02- present, $108,899 A Survey to Assess the Incidence and Characteristics of Melanoma in Parkinson's disease (PD) Patients (Protocol EP002)1/03-present. $112,500 A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson’s Disease Patients (Study for Proof of Concept in Early Parkinson’s Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE). Protocol # 1198.100, 8/03 to 3/04. $218,500

22

Stroke Occurrence Prevention Program in African American Adults, Protocol 1470376583A1, Department of Health and Human Services (NIH), 10/3/03 – present. $1,000,000 Abciximab (ReoPro®) in Acute Ischemic Stroke: A Phase III, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled Trial (Protocol C0116T41) 2/03 to present, $72,000 Implications of Motor Fluctuations in Parkinson's Patients on Chronic Therapy (IMPACT) Registry 2/03 to present, $1500 Feasibility Study on the use of a Parkinson’s Disease Symptoms Diary for the Planned Phase III Studies with Sarizotan (EMR 62 225) 3/03 to present, $6000 A Long-Term, Multicenter, Open-Label Safety Study with Oral 20 or 40 mg/d Doses of KW-6002 (Istradefylline) as Treatment for Parkinson’s Disease in Patients with Motor Response Complications on Levodopa Therapy, 1//04 to present A 12-week, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Multicenter, Fixed Dose-Response Study to Evaluate the Efficacy and Safety of 10, 20 and 40 mg/d Oral Doses of KW-6002 (Istradefylline) as Treatment for Parkinson’s Disease in Patients with Motor Response Complications on Levodopa/Carbidopa Therapy, 06/04 to 12/05 A double-blind, placebo-controlled, multicenter, multinational Phase III study to evaluate the safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from treatment-associated dyskinesia (EMR 62 225-019; PADDY 2), 8/05 to present A Phase 2, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Multicenter Study of the Efficacy and Safety of 40 mg/day KW-6002 (Istradefylline) As Monotherapy in Subjects with Parkinson’s Disease, 8/05 to present

A Multi-center, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson’s Disease Subjects, Protocol: TVP-1012/500, 12/05 to present

Updated, July 10, 2007